Viatris Scoops Another Preferred Formulary Listing For Interchangeable Semglee
Prime Therapeutics Decision For Insulin Glargine Biosimilar Follows Express Scripts
Executive Summary
Prime Therapeutics, the large PBM serving tens of millions of members, insisted it was “not beholden to rebates” as it joined Express Scripts in announcing plans to move Viatris/Biocon’s interchangeable biosimilar insulin glargine products to its preferred national formulary.
You may also be interested in...
Lilly Gets Second Interchangeable Insulin Glargine In US
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.
Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.